JP2022535998A - Shp2ホスファターゼアロステリック阻害物質 - Google Patents
Shp2ホスファターゼアロステリック阻害物質 Download PDFInfo
- Publication number
- JP2022535998A JP2022535998A JP2021574766A JP2021574766A JP2022535998A JP 2022535998 A JP2022535998 A JP 2022535998A JP 2021574766 A JP2021574766 A JP 2021574766A JP 2021574766 A JP2021574766 A JP 2021574766A JP 2022535998 A JP2022535998 A JP 2022535998A
- Authority
- JP
- Japan
- Prior art keywords
- dihydrospiro
- indene
- carboxylate
- tert
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 title claims abstract description 13
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 title claims abstract description 13
- 229940125528 allosteric inhibitor Drugs 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 62
- 239000003112 inhibitor Substances 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 230000003287 optical effect Effects 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 53
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 21
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
- -1 -SO2CH3 Chemical group 0.000 claims description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 230000003281 allosteric effect Effects 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 111
- 239000000243 solution Substances 0.000 description 103
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 95
- 238000000034 method Methods 0.000 description 68
- 239000000047 product Substances 0.000 description 67
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 239000007858 starting material Substances 0.000 description 47
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 34
- 239000002904 solvent Substances 0.000 description 34
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 239000012043 crude product Substances 0.000 description 29
- 239000012074 organic phase Substances 0.000 description 28
- 238000004440 column chromatography Methods 0.000 description 27
- 238000000746 purification Methods 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 14
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 14
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- IXEXQYZAPGSKJC-UHFFFAOYSA-N ethyl 3-chloro-6-(2,3-dichlorophenyl)-5-methylpyrazine-2-carboxylate Chemical compound ClC=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)C(=O)OCC IXEXQYZAPGSKJC-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 7
- PHBLTZGIJWYGRO-RUZDIDTESA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(C)(C)O)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(C)(C)O)CO)C5=C(C(=CC=C5)Cl)Cl PHBLTZGIJWYGRO-RUZDIDTESA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- GHRIDABVKDEQNS-UHFFFAOYSA-N ethyl 6-bromo-3-chloro-5-methylpyrazine-2-carboxylate Chemical compound BrC1=C(N=C(C(=N1)C(=O)OCC)Cl)C GHRIDABVKDEQNS-UHFFFAOYSA-N 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- OFJNGXHQTKATOD-XMMPIXPASA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C(=CC=C4)C#N)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C(=CC=C4)C#N)CO)C5=C(C(=CC=C5)Cl)Cl OFJNGXHQTKATOD-XMMPIXPASA-N 0.000 description 4
- GEGXIKLXHRPATG-XMMPIXPASA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=CC(=C4)NS(=O)(=O)C)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=CC(=C4)NS(=O)(=O)C)CO)C5=C(C(=CC=C5)Cl)Cl GEGXIKLXHRPATG-XMMPIXPASA-N 0.000 description 4
- QZVPQHQOTGSUAB-HSZRJFAPSA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C#N)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C#N)C5=C(C(=CC=C5)Cl)Cl QZVPQHQOTGSUAB-HSZRJFAPSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 4
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- NIPZZXUFJPQHNH-UHFFFAOYSA-M pyrazine-2-carboxylate Chemical compound [O-]C(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-M 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- XWTMEQYXJSJHHO-JOCHJYFZSA-N 3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazine-2-carboxamide Chemical compound C1(C(=O)N)=NC(C2=C(C(=CC=C2)Cl)Cl)=C(N=C1N1CCC2(CC1)CC1=CC=CC=C1[C@H]2N)C XWTMEQYXJSJHHO-JOCHJYFZSA-N 0.000 description 3
- XBRNQAVLAWNHIC-UHFFFAOYSA-N 4-[(3-bromophenyl)methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(C(O)=O)CC1=CC=CC(Br)=C1 XBRNQAVLAWNHIC-UHFFFAOYSA-N 0.000 description 3
- RPKQCGKQVIDFQV-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC2(CC1)CC3=C(C2=O)C(=CC=C3)Br Chemical compound CC(C)(C)OC(=O)N1CCC2(CC1)CC3=C(C2=O)C(=CC=C3)Br RPKQCGKQVIDFQV-UHFFFAOYSA-N 0.000 description 3
- XPGPDCNYCNPBKC-UHFFFAOYSA-N CC1=C(N=C(C(=N1)Cl)C(=O)N)C2=C(C(=CC=C2)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)Cl)C(=O)N)C2=C(C(=CC=C2)Cl)Cl XPGPDCNYCNPBKC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000009987 spinning Methods 0.000 description 3
- RRAMTOSLXCIPSZ-UHFFFAOYSA-N tert-butyl 5-bromo-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2(CC3=CC=C(Br)C=C3C2=O)CC1 RRAMTOSLXCIPSZ-UHFFFAOYSA-N 0.000 description 3
- TYIKXPOMOYDGCS-UHFFFAOYSA-N (2,3-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1Cl TYIKXPOMOYDGCS-UHFFFAOYSA-N 0.000 description 2
- LOCGPWGCRVKCFN-UHFFFAOYSA-N (2-chloro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(Cl)=C1 LOCGPWGCRVKCFN-UHFFFAOYSA-N 0.000 description 2
- DVFVYGOJZOUJJB-UHFFFAOYSA-N 1-o-tert-butyl 4-o-ethyl 4-[(4-bromophenyl)methyl]piperidine-1,4-dicarboxylate Chemical compound C=1C=C(Br)C=CC=1CC1(C(=O)OCC)CCN(C(=O)OC(C)(C)C)CC1 DVFVYGOJZOUJJB-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- BEDDMOXMVCQKNJ-UHFFFAOYSA-N 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyridine Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CN=C1C(F)(F)F BEDDMOXMVCQKNJ-UHFFFAOYSA-N 0.000 description 2
- IJOSVNBGIKAARU-UHFFFAOYSA-N 3-chloro-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=NC=CC=C1Cl IJOSVNBGIKAARU-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- CJUMDGADQJSSKK-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1(C(O)=O)CC1=CC=C(Br)C=C1 CJUMDGADQJSSKK-UHFFFAOYSA-N 0.000 description 2
- JEDALECUOKHQDK-UHFFFAOYSA-M 4-ethyl-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylate Chemical compound CCC1(C([O-])=O)CCN(C(=O)OC(C)(C)C)CC1 JEDALECUOKHQDK-UHFFFAOYSA-M 0.000 description 2
- DZANYXOTJVLAEE-UHFFFAOYSA-N 6,8-difluoro-4-methylumbelliferyl phosphate Chemical compound FC1=C(OP(O)(O)=O)C(F)=CC2=C1OC(=O)C=C2C DZANYXOTJVLAEE-UHFFFAOYSA-N 0.000 description 2
- LLENVBUPWUQAGL-UHFFFAOYSA-N 6,8-difluoro-7-hydroxy-4-methylcoumarin Chemical compound FC1=C(O)C(F)=CC2=C1OC(=O)C=C2C LLENVBUPWUQAGL-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- RXWGHOMBWXUXRN-UHFFFAOYSA-N C(=O)(OC(C)(C)C)N(C1=NC=CC(=C1Cl)I)C(=O)OC(C)(C)C Chemical compound C(=O)(OC(C)(C)C)N(C1=NC=CC(=C1Cl)I)C(=O)OC(C)(C)C RXWGHOMBWXUXRN-UHFFFAOYSA-N 0.000 description 2
- TWMWCGFADRCABH-UHFFFAOYSA-N C1=CC(=C(C(=C1)Cl)Cl)C2=CN=C(C(=N2)C(=O)O)Cl Chemical compound C1=CC(=C(C(=C1)Cl)Cl)C2=CN=C(C(=N2)C(=O)O)Cl TWMWCGFADRCABH-UHFFFAOYSA-N 0.000 description 2
- GYXBQFJYNLGHKR-JOCHJYFZSA-N C1CN(CCC12CC3=CC=CC=C3[C@H]2N)C4=NC=C(N=C4CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound C1CN(CCC12CC3=CC=CC=C3[C@H]2N)C4=NC=C(N=C4CO)C5=C(C(=CC=C5)Cl)Cl GYXBQFJYNLGHKR-JOCHJYFZSA-N 0.000 description 2
- ONHYSXRYQDBWMR-QUZMYUOTSA-N CC(C)(C)OC(N(CC1)CCC1(CC1=CC=CC(C#N)=C11)[C@H]1NS(C(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(CC1=CC=CC(C#N)=C11)[C@H]1NS(C(C)(C)C)=O)=O ONHYSXRYQDBWMR-QUZMYUOTSA-N 0.000 description 2
- YMFWUPIAKBJSTB-CQWFHMBZSA-N CC(C)(C)[S@@](=O)N[C@@H]1C2=CC=CC=C2CC13CCNCC3.C(=O)(C(F)(F)F)O Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1C2=CC=CC=C2CC13CCNCC3.C(=O)(C(F)(F)F)O YMFWUPIAKBJSTB-CQWFHMBZSA-N 0.000 description 2
- GDEZYZDCCSOPGY-UHFFFAOYSA-N CC1=C(N=C(C(=N1)Cl)C#N)C2=C(C(=CC=C2)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)Cl)C#N)C2=C(C(=CC=C2)Cl)Cl GDEZYZDCCSOPGY-UHFFFAOYSA-N 0.000 description 2
- WAIQKUOAWIADDP-XMMPIXPASA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C#N)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C#N)CO)C5=C(C(=CC=C5)Cl)Cl WAIQKUOAWIADDP-XMMPIXPASA-N 0.000 description 2
- KKPSDXXWXQDTEQ-HSZRJFAPSA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(=O)N)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(=O)N)CO)C5=C(C(=CC=C5)Cl)Cl KKPSDXXWXQDTEQ-HSZRJFAPSA-N 0.000 description 2
- MSVXCXSVZSZNIF-JOCHJYFZSA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=CC=N4)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=CC=N4)CO)C5=C(C(=CC=C5)Cl)Cl MSVXCXSVZSZNIF-JOCHJYFZSA-N 0.000 description 2
- CTXKUHGOKVCLOB-OAQYLSRUSA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)CO)C5=C(C(=NC=C5)N)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)CO)C5=C(C(=NC=C5)N)Cl CTXKUHGOKVCLOB-OAQYLSRUSA-N 0.000 description 2
- XKBSKPHBTJXQPJ-OAQYLSRUSA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)CO)C5=C(N=CC=C5)C(F)(F)F Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)CO)C5=C(N=CC=C5)C(F)(F)F XKBSKPHBTJXQPJ-OAQYLSRUSA-N 0.000 description 2
- QCZXYHLKRQKVTR-UHFFFAOYSA-N CC1=CC2=C(CC3(C2=O)CCN(CC3)C(=O)OC(C)(C)C)N=C1 Chemical compound CC1=CC2=C(CC3(C2=O)CCN(CC3)C(=O)OC(C)(C)C)N=C1 QCZXYHLKRQKVTR-UHFFFAOYSA-N 0.000 description 2
- NNLIZLQSOFBHFZ-UHFFFAOYSA-N CCOC(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)CC2=CC(=CC=C2)Br Chemical compound CCOC(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)CC2=CC(=CC=C2)Br NNLIZLQSOFBHFZ-UHFFFAOYSA-N 0.000 description 2
- GOLBDGJQLWBGFQ-UHFFFAOYSA-N CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=C(C(=NC=C2)N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=C(C(=NC=C2)N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)Cl GOLBDGJQLWBGFQ-UHFFFAOYSA-N 0.000 description 2
- RPODFFPFRWAEQL-UHFFFAOYSA-N CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=C(N=CC=C2)C(F)(F)F Chemical compound CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=C(N=CC=C2)C(F)(F)F RPODFFPFRWAEQL-UHFFFAOYSA-N 0.000 description 2
- UZVJZUIZMMWFBB-UHFFFAOYSA-N CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=CC(=NC(=C2Cl)Cl)NC(=O)OC(C)(C)C Chemical compound CCOC(=O)C1=NC(=C(N=C1Cl)C)C2=CC(=NC(=C2Cl)Cl)NC(=O)OC(C)(C)C UZVJZUIZMMWFBB-UHFFFAOYSA-N 0.000 description 2
- IWSKZIKVNZLDSD-RUZDIDTESA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C#N)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C#N)C)C5=C(C(=CC=C5)Cl)Cl IWSKZIKVNZLDSD-RUZDIDTESA-N 0.000 description 2
- FUWJGPBZKKQOOV-UHFFFAOYSA-N COC(=O)C1=NC(=CN=C1Cl)C2=C(C(=CC=C2)Cl)Cl Chemical compound COC(=O)C1=NC(=CN=C1Cl)C2=C(C(=CC=C2)Cl)Cl FUWJGPBZKKQOOV-UHFFFAOYSA-N 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102000014400 SH2 domains Human genes 0.000 description 2
- 108050003452 SH2 domains Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- DKKQZPVCISDBHD-HSZRJFAPSA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical compound C(C1=NC(C2=C(C(=CC=C2)Cl)Cl)=C(N=C1N1CCC2(CC1)[C@H](N)C1=C(C=CC=C1)C2)C)O DKKQZPVCISDBHD-HSZRJFAPSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- GZHAHULRVVGLSE-XMMPIXPASA-N ethyl 3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazine-2-carboxylate Chemical compound C1(C(=O)OCC)=NC(=C(N=C1N1CCC2([C@H](N)C3=C(C2)C=CC=C3)CC1)C)C1=C(C(=CC=C1)Cl)Cl GZHAHULRVVGLSE-XMMPIXPASA-N 0.000 description 2
- POYHGPKBZHOUBJ-UHFFFAOYSA-N ethyl 5-bromo-6-methyl-2-oxo-1h-pyrazine-3-carboxylate Chemical compound CCOC(=O)C1=NC(Br)=C(C)N=C1O POYHGPKBZHOUBJ-UHFFFAOYSA-N 0.000 description 2
- LZJZHTZAUNNQGU-UHFFFAOYSA-N ethyl 6-methyl-2-oxo-1h-pyrazine-3-carboxylate Chemical compound CCOC(=O)C1=NC=C(C)N=C1O LZJZHTZAUNNQGU-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- ONHYSXRYQDBWMR-HZAQMHFWSA-N tert-butyl (1S)-1-[[(R)-tert-butylsulfinyl]amino]-7-cyanospiro[1,3-dihydroindene-2,4'-piperidine]-1'-carboxylate Chemical compound C(#N)C=1C=CC=C2CC3(CCN(CC3)C(=O)OC(C)(C)C)[C@@H](C=12)N[S@](=O)C(C)(C)C ONHYSXRYQDBWMR-HZAQMHFWSA-N 0.000 description 2
- JAVVVDPMHHHPQO-KWMCUTETSA-N tert-butyl (1S)-1-[[(R)-tert-butylsulfinyl]amino]spiro[1,3-dihydroindene-2,4'-piperidine]-1'-carboxylate Chemical compound C(C)(C)([S@@](=O)N[C@H]1C2(CCN(CC2)C(=O)OC(C)(C)C)CC2=C1C=CC=C2)C JAVVVDPMHHHPQO-KWMCUTETSA-N 0.000 description 2
- DYNFTZOGEORYHU-JGCGQSQUSA-N tert-butyl 3-[(R)-tert-butylsulfinyl]imino-5-(methanesulfonamido)spiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2(CC1)CC3=C(C2=N[S@](=O)C(C)(C)C)C=C(C=C3)NS(=O)(=O)C DYNFTZOGEORYHU-JGCGQSQUSA-N 0.000 description 2
- GXWIIEFIDCPXTM-SSEXGKCCSA-N tert-butyl 3-[(R)-tert-butylsulfinyl]imino-5-cyanospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2(CC1)CC3=C(C2=N[S@](=O)C(C)(C)C)C=C(C=C3)C#N GXWIIEFIDCPXTM-SSEXGKCCSA-N 0.000 description 2
- MNYFDSIEHMMRPG-UHFFFAOYSA-N tert-butyl 4-(2-chloropyridine-3-carbonyl)-4-methylpiperidine-1-carboxylate Chemical compound ClC1=C(C(=O)C2(CCN(CC2)C(=O)OC(C)(C)C)C)C=CC=N1 MNYFDSIEHMMRPG-UHFFFAOYSA-N 0.000 description 2
- WRHWHEZSKPZFPH-UHFFFAOYSA-N tert-butyl 4-[(2-chloropyridin-3-yl)-hydroxymethyl]-4-methylpiperidine-1-carboxylate Chemical compound ClC1=NC=CC=C1C(C1(CCN(CC1)C(=O)OC(C)(C)C)C)O WRHWHEZSKPZFPH-UHFFFAOYSA-N 0.000 description 2
- MDAJUGBGFRKTNC-UHFFFAOYSA-N tert-butyl 4-cyano-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C(#N)C=1C=CC=C2CC3(CCN(CC3)C(=O)OC(C)(C)C)C(C=12)=O MDAJUGBGFRKTNC-UHFFFAOYSA-N 0.000 description 2
- TUGBXBFQDMCNDH-UHFFFAOYSA-N tert-butyl 5-(methanesulfonamido)-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound N1(CCC2(CC1)CC1=CC=C(NS(=O)(=O)C)C=C1C2=O)C(=O)OC(C)(C)C TUGBXBFQDMCNDH-UHFFFAOYSA-N 0.000 description 2
- MFDPPILQIZUTNQ-UHFFFAOYSA-N tert-butyl 5-cyano-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(CCC21C(=O)C1=C(C=CC(C#N)=C1)C2)C(=O)OC(C)(C)C MFDPPILQIZUTNQ-UHFFFAOYSA-N 0.000 description 2
- XERINNKAUNZHCF-UHFFFAOYSA-N tert-butyl 6-bromo-3-oxospiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound O=C1C2(CCN(CC2)C(=O)OC(C)(C)C)CC2=CC(Br)=CC=C12 XERINNKAUNZHCF-UHFFFAOYSA-N 0.000 description 2
- LFYCTMVAEJFARR-UHFFFAOYSA-N tert-butyl N-(3-chloro-5-iodopyridin-2-yl)-N-[(2-methylpropan-2-yl)oxycarbonyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C1=C(C=C(C=N1)I)Cl)C(=O)OC(C)(C)C LFYCTMVAEJFARR-UHFFFAOYSA-N 0.000 description 2
- KPVGSBWJGVRKFU-UHFFFAOYSA-N tert-butyl N-(5,6-dichloropyridin-2-yl)carbamate Chemical compound ClC=1C=CC(=NC=1Cl)NC(OC(C)(C)C)=O KPVGSBWJGVRKFU-UHFFFAOYSA-N 0.000 description 2
- UEYNRRQJJHZENW-UHFFFAOYSA-N tert-butyl n-(6-chloropyridin-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(Cl)=N1 UEYNRRQJJHZENW-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- ABRTZUPJNVJMHP-UHFFFAOYSA-N (2,3-dichloropyridin-4-yl)boronic acid Chemical compound OB(O)C1=CC=NC(Cl)=C1Cl ABRTZUPJNVJMHP-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- MJADWSULPPPIKV-UOBPVEMNSA-N (R)-N-[(1S)-1'-[3-cyano-5-(2,3-dichlorophenyl)-6-methylpyrazin-2-yl]spiro[1,3-dihydroindene-2,4'-piperidine]-1-yl]-2-methylpropane-2-sulfinamide Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N[S@](=O)C(C)(C)C)C#N)C5=C(C(=CC=C5)Cl)Cl MJADWSULPPPIKV-UOBPVEMNSA-N 0.000 description 1
- ZPCJPJQUVRIILS-UHFFFAOYSA-N 1-bromo-3-(bromomethyl)benzene Chemical compound BrCC1=CC=CC(Br)=C1 ZPCJPJQUVRIILS-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 1
- GXZDYRYYNXYPMQ-UHFFFAOYSA-N 2-chloro-6-methylpyridine Chemical group CC1=CC=CC(Cl)=N1 GXZDYRYYNXYPMQ-UHFFFAOYSA-N 0.000 description 1
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- SMZAZDGFGOHROS-UHFFFAOYSA-N 3-bromo-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=NC=CC=C1Br SMZAZDGFGOHROS-UHFFFAOYSA-N 0.000 description 1
- GTTQRVGVEIXEHQ-UHFFFAOYSA-N 3-chloro-4-iodopyridin-2-amine Chemical compound NC1=NC=CC(I)=C1Cl GTTQRVGVEIXEHQ-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OBYJTLDIQBWBHM-UHFFFAOYSA-N 6-chloropyridin-2-amine Chemical compound NC1=CC=CC(Cl)=N1 OBYJTLDIQBWBHM-UHFFFAOYSA-N 0.000 description 1
- VSNOBKPJDUVTNI-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC2(CC1)CC3=C(C2=O)C=CC(=C3)NS(=O)(=O)C Chemical compound CC(C)(C)OC(=O)N1CCC2(CC1)CC3=C(C2=O)C=CC(=C3)NS(=O)(=O)C VSNOBKPJDUVTNI-UHFFFAOYSA-N 0.000 description 1
- BYXZUALMZWIGMT-WTPASJBYSA-N CC(C)(C)OC(N(CC1)CCC1(CC(C1=C2)=CC=C2C(N)=O)[C@@H]1N[S@@](C(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(CC(C1=C2)=CC=C2C(N)=O)[C@@H]1N[S@@](C(C)(C)C)=O)=O BYXZUALMZWIGMT-WTPASJBYSA-N 0.000 description 1
- SJGCIIZUYYSBGR-AYLZSAKASA-N CC(C)(C)OC(N(CC1)CCC1(CC(C1=C2)=CC=C2NS(C)(=O)=O)[C@@H]1N[S@@](C(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(CC(C1=C2)=CC=C2NS(C)(=O)=O)[C@@H]1N[S@@](C(C)(C)C)=O)=O SJGCIIZUYYSBGR-AYLZSAKASA-N 0.000 description 1
- QTLORHKTTMSZOH-AYLZSAKASA-N CC(C)(C)OC(N(CC1)CCC1(CC1=CC(NS(C)(=O)=O)=CC=C11)[C@@H]1N[S@@](C(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1(CC1=CC(NS(C)(=O)=O)=CC=C11)[C@@H]1N[S@@](C(C)(C)C)=O)=O QTLORHKTTMSZOH-AYLZSAKASA-N 0.000 description 1
- UFNCGVYDEUDNNT-CRICUBBOSA-N CC(C)(C)[S@@](=O)N[C@@H]1C2=C(CC13CCNCC3)C=CC(=C2)C(C)(C)O Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1C2=C(CC13CCNCC3)C=CC(=C2)C(C)(C)O UFNCGVYDEUDNNT-CRICUBBOSA-N 0.000 description 1
- BHCUGESORVKVGD-IWIKFHKFSA-N CC(C)(C)[S@](N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C1=NC(C)=C(C(C=CC=C2Cl)=C2Cl)N=C1C(N)=O)=O Chemical compound CC(C)(C)[S@](N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C1=NC(C)=C(C(C=CC=C2Cl)=C2Cl)N=C1C(N)=O)=O BHCUGESORVKVGD-IWIKFHKFSA-N 0.000 description 1
- YDDZBADZQNZJLC-PLTNMMHCSA-N CC(C)([S@@](=O)N[C@@H]1C2=CC(C(=O)C)=CC=C2CC21CCN(CC2)C(=O)OC(C)(C)C)C Chemical compound CC(C)([S@@](=O)N[C@@H]1C2=CC(C(=O)C)=CC=C2CC21CCN(CC2)C(=O)OC(C)(C)C)C YDDZBADZQNZJLC-PLTNMMHCSA-N 0.000 description 1
- WTHHBYBPEKRUGV-XMMPIXPASA-N CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)NS(=O)(=O)C)CO)C5=C(C(=CC=C5)Cl)Cl Chemical compound CC1=C(N=C(C(=N1)N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)NS(=O)(=O)C)CO)C5=C(C(=CC=C5)Cl)Cl WTHHBYBPEKRUGV-XMMPIXPASA-N 0.000 description 1
- BICBJYACLFTHNF-RUZDIDTESA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C(=CC=C4)C#N)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C(=CC=C4)C#N)C)C5=C(C(=CC=C5)Cl)Cl BICBJYACLFTHNF-RUZDIDTESA-N 0.000 description 1
- FASNQTFTDIKYFO-XMMPIXPASA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(=O)N)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(=O)N)C)C5=C(C(=CC=C5)Cl)Cl FASNQTFTDIKYFO-XMMPIXPASA-N 0.000 description 1
- VNKIULREMCWXAZ-AREMUKBSSA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(C)(C)O)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=C(C=C4)C(C)(C)O)C)C5=C(C(=CC=C5)Cl)Cl VNKIULREMCWXAZ-AREMUKBSSA-N 0.000 description 1
- DQSDUDDUGGAGPK-RUZDIDTESA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=CC(=C4)NS(=O)(=O)C)C)C5=C(C(=CC=C5)Cl)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=C([C@H]3N)C=CC(=C4)NS(=O)(=O)C)C)C5=C(C(=CC=C5)Cl)Cl DQSDUDDUGGAGPK-RUZDIDTESA-N 0.000 description 1
- KACLWGCPUMDUHK-JOCHJYFZSA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C)C5=C(C(=NC=C5)N)Cl Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C)C5=C(C(=NC=C5)N)Cl KACLWGCPUMDUHK-JOCHJYFZSA-N 0.000 description 1
- VJOIPRJLVQYCLI-JOCHJYFZSA-N CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C)C5=C(N=CC=C5)C(F)(F)F Chemical compound CCOC(=O)C1=NC(=C(N=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C)C5=C(N=CC=C5)C(F)(F)F VJOIPRJLVQYCLI-JOCHJYFZSA-N 0.000 description 1
- GVWKNTTUJKAQSJ-HOHRNCFUSA-N CCOC(C1=NC(C(C=CC=C2Cl)=C2Cl)=C(C)N=C1N(CC1)CCC1(CC(C1=C2)=CC=C2C#N)[C@@H]1N[S@@](C(C)(C)C)=O)=O Chemical compound CCOC(C1=NC(C(C=CC=C2Cl)=C2Cl)=C(C)N=C1N(CC1)CCC1(CC(C1=C2)=CC=C2C#N)[C@@H]1N[S@@](C(C)(C)C)=O)=O GVWKNTTUJKAQSJ-HOHRNCFUSA-N 0.000 description 1
- UJLXYFIJGQCGHZ-MOADPPEFSA-N CCOC(C1=NC(C(C=CC=C2Cl)=C2Cl)=C(C)N=C1N(CC1)CCC1(CC(C1=C2)=CC=C2C(N)=O)[C@@H]1N[S@@](C(C)(C)C)=O)=O Chemical compound CCOC(C1=NC(C(C=CC=C2Cl)=C2Cl)=C(C)N=C1N(CC1)CCC1(CC(C1=C2)=CC=C2C(N)=O)[C@@H]1N[S@@](C(C)(C)C)=O)=O UJLXYFIJGQCGHZ-MOADPPEFSA-N 0.000 description 1
- GMYMTFSEFHYFNF-VEISUWESSA-N CCOC(C1=NC(C(C=CC=C2Cl)=C2Cl)=C(C)N=C1N(CC1)CCC1(CC1=CC(NS(C)(=O)=O)=CC=C11)[C@@H]1N[S@@](C(C)(C)C)=O)=O Chemical compound CCOC(C1=NC(C(C=CC=C2Cl)=C2Cl)=C(C)N=C1N(CC1)CCC1(CC1=CC(NS(C)(=O)=O)=CC=C11)[C@@H]1N[S@@](C(C)(C)C)=O)=O GMYMTFSEFHYFNF-VEISUWESSA-N 0.000 description 1
- VSENPHLFBMTCBX-DPJMWLGRSA-N CCOC(C1=NC(C(C=CC=C2Cl)=C2Cl)=C(C)N=C1N(CC1)CCC1(CC1=CC=C(C(C)(C)O)C=C11)[C@@H]1N[S@@](C(C)(C)C)=O)=O Chemical compound CCOC(C1=NC(C(C=CC=C2Cl)=C2Cl)=C(C)N=C1N(CC1)CCC1(CC1=CC=C(C(C)(C)O)C=C11)[C@@H]1N[S@@](C(C)(C)C)=O)=O VSENPHLFBMTCBX-DPJMWLGRSA-N 0.000 description 1
- VDJXLNWQMCVJOR-VEISUWESSA-N CCOC(C1=NC(C(C=CC=C2Cl)=C2Cl)=C(C)N=C1N(CC1)CCC1(CC1=CC=CC(NS(C)(=O)=O)=C11)[C@@H]1N[S@@](C(C)(C)C)=O)=O Chemical compound CCOC(C1=NC(C(C=CC=C2Cl)=C2Cl)=C(C)N=C1N(CC1)CCC1(CC1=CC=CC(NS(C)(=O)=O)=C11)[C@@H]1N[S@@](C(C)(C)C)=O)=O VDJXLNWQMCVJOR-VEISUWESSA-N 0.000 description 1
- IYOKQNJIWQMZPP-JOCHJYFZSA-N COC(=O)C1=NC(=CN=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C5=C(C(=CC=C5)Cl)Cl Chemical compound COC(=O)C1=NC(=CN=C1N2CCC3(CC2)CC4=CC=CC=C4[C@H]3N)C5=C(C(=CC=C5)Cl)Cl IYOKQNJIWQMZPP-JOCHJYFZSA-N 0.000 description 1
- IRJJRQQUUAVVAO-AJWVYOOVSA-N C[C@@H](CC1=CC=C(CC(CC2)(CCN2C2=NC(C)=C(C(C=CC=C3Cl)=C3Cl)N=C2CO)C2N)C2=C1)O Chemical compound C[C@@H](CC1=CC=C(CC(CC2)(CCN2C2=NC(C)=C(C(C=CC=C3Cl)=C3Cl)N=C2CO)C2N)C2=C1)O IRJJRQQUUAVVAO-AJWVYOOVSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 101150048674 PTPN11 gene Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229930189065 blasticidin Natural products 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- DBKKFIIYQGGHJO-UHFFFAOYSA-N diethyl 2-oxopropanedioate Chemical compound CCOC(=O)C(=O)C(=O)OCC DBKKFIIYQGGHJO-UHFFFAOYSA-N 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- XGZNHFPFJRZBBT-UHFFFAOYSA-N ethanol;titanium Chemical compound [Ti].CCO.CCO.CCO.CCO XGZNHFPFJRZBBT-UHFFFAOYSA-N 0.000 description 1
- IRKBPZGHGQPMIW-UHFFFAOYSA-N ethyl 6-bromo-3-chloropyrazine-2-carboxylate Chemical compound CCOC(=O)c1nc(Br)cnc1Cl IRKBPZGHGQPMIW-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MLSKXPOBNQFGHW-UHFFFAOYSA-N methoxy(dioxido)borane Chemical compound COB([O-])[O-] MLSKXPOBNQFGHW-UHFFFAOYSA-N 0.000 description 1
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000000711 polarimetry Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000276 potassium ferrocyanide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- RNGJLYYTTIMONR-HZAQMHFWSA-N tert-butyl (1S)-1-[[(R)-tert-butylsulfinyl]amino]-6-cyanospiro[1,3-dihydroindene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)([S@@](=O)N[C@H]1C2(CCN(CC2)C(=O)OC(C)(C)C)CC2=CC=C(C#N)C=C12)C RNGJLYYTTIMONR-HZAQMHFWSA-N 0.000 description 1
- PDIIAMGIEONAGN-JGCGQSQUSA-N tert-butyl 3-[(R)-tert-butylsulfinyl]imino-6-(methanesulfonamido)spiro[1H-indene-2,4'-piperidine]-1'-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC2(CC1)CC3=C(C2=N[S@](=O)C(C)(C)C)C=CC(=C3)NS(=O)(=O)C PDIIAMGIEONAGN-JGCGQSQUSA-N 0.000 description 1
- WYDRCMKCBWMSNK-UHFFFAOYSA-N tert-butyl 3-oxospiro[1h-indene-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11C(=O)C2=CC=CC=C2C1 WYDRCMKCBWMSNK-UHFFFAOYSA-N 0.000 description 1
- LMKGOFDRKIAUPZ-UHFFFAOYSA-N tert-butyl 4-formyl-4-methylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C)(C=O)CC1 LMKGOFDRKIAUPZ-UHFFFAOYSA-N 0.000 description 1
- IIEMEFZYFPCYBC-UHFFFAOYSA-N tert-butyl 5-oxospiro[7h-cyclopenta[b]pyridine-6,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11C(=O)C2=CC=CN=C2C1 IIEMEFZYFPCYBC-UHFFFAOYSA-N 0.000 description 1
- FQZLNQAUUMSUHT-UHFFFAOYSA-N tert-butyl n,n-bis(2-chloroethyl)carbamate Chemical compound CC(C)(C)OC(=O)N(CCCl)CCCl FQZLNQAUUMSUHT-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
R1およびR2はそれぞれ、-CH3、-NH2、-CH2OH、-C(O)O(CH2)nCH3、-CN、-H、-OH、-C(O)NH2または-CH(OH)CH3から独立して選択され;
R3は、H、C1-6アルキル、-CF3、ハロゲン、-SO2CH3、-OCH3、-CN、-C(O)NH2、-NHnSO3-m(CH3)m、-CHn(CH3)mOH、-OCF3または-C(O)CH3から選択され;
Y1、Y2、Y3およびY4はそれぞれ、-C-または-N-から独立して選択され;
n=0または1であり;そして
m=1または2である]
の構造を有する。
R1およびR2はそれぞれ、-H、-CH3、-NH2、-C(O)O(CH2)nCH3、-CN、-OH、-CH2OH、-C(O)NH2または-CH(OH)CH3から独立して選択され;
R3は、H、C1-6アルキル、-CF3、ハロゲン、-SO2CH3、-OCH3、-CN、-C(O)NH2、-NHnSO3-m(CH3)m、-CHn(CH3)2-nOH、-C(O)CH3または-OCF3から選択され;
R4、R5、R6、R7およびR8はそれぞれ、-H、-Cl、-CH3、-Br、-CF3、CH3O-、CH3SO2-、=O、CH3NH-および-NH2から独立して選択され;
Y1、Y2、Y3およびY4はそれぞれ、CまたはNから独立して選択され;
n=0または1であり;そして
m=1または2である]
の構造を有する。
Y1、Y2、Y3およびY4はそれぞれ、NまたはCから独立して選択され;
R3は、H、ハロゲン、-CN、-CONH2、-NSO(CH3)2、-CF3、-CH3、-OCF3、-SO2CH3または-OCH3から選択される]
の構造を有する。
R3は、H、-CH3、-OCH3、-CNまたはハロゲンから選択され;
R2は、-CH2OHまたは-C(O)O(CH2)nCH3から選択され;そして
n=1である]
の構造を有する。
Y1は、CまたはNから選択され;
R3は、H、-CH3、-OCH3、-CNまたはハロゲンから選択され、
R4、R5およびR6はそれぞれ、-H、ハロゲン、-CH3、-CF3、-OCH3、-CN、-NHR、-N(CH3)2または-NH2から独立して選択され;
Rは、C1-3アルキルまたはシクロアルキルであり;そして
n=0または1である]
の構造を有する。
R2は、-CH2OHまたは-C(O)OCH3から選択され;
R3は、H、ハロゲン、-CF3、-OCH3、-OCF3、-CN、-C(O)NH2、-NHnSO3-m(CH3)m、C1-6アルキルまたはCH3SO2-から選択され;
R4、R5およびR6はそれぞれ、H、ハロゲン、-CF3、アルコキシ、CH3NH-、CH3SO2-またはC1-3置換もしくは非置換アルキルから独立して選択され;
n=0または1であり;そして
m=1または2である]
の構造を有する。
以下の実施例は非限定的な例示であり、本発明を何ら限定するものではない。本発明の精神を逸脱しない範囲の変形、変更および修正は、本発明の範囲内である。
LC-MS, (ES, m/z): [M+H]+ = 183.
LC-MS, (ES, m/z): [M+H]+ = 261.
LC-MS, (ES, m/z): [M+H]+ = 279.
LC-MS, (ES, m/z) : [M+H]+ = 345.
LC-MS, (ES, m/z) : [M+H]+ = 302.
LC-MS, (ES, m/z): [M+H]+=404.
LC-MS, (ES, m/z): [M+H]+=406.
LC-MS, (ES, m/z):[M+H]+=307.
LC-MS, (ES, m/z):[M+H]+=615.
LC-MS, (ES, m/z): [M+H]+=511.
LC-MS, (ES, m/z): [M+H]+=469.
1H NMR (400 MHz, D6-DMSO) δ = 7.74 (dd, J = 7.9 Hz, 1.7, 1H), 7.49 (t, J = 7.8 Hz, 1H), 7.44 (dd, J =7.6 Hz, 1.7 Hz, 1H), 7.39 - 7.33 (m, 1H), 7.26 - 7.15 (m, 3H), 5.29 (t, J = 5.8 Hz, 1H), 4.53 (d, J = 5.7 Hz, 2H), 3.98 (s, 1H), 3.80 - 3.70 (m, 2H), 3.15 - 3.05 (m, 3H), 2.69 (d, J = 15.8 Hz, 1H), 2.20 (s, 3H), 1.92 - 1.82 (m, 2H), 1.57 (d, J = 12.5 Hz, 1H), 1.27 - 1.24 (m, 1H).
(S)-1-アミノ-1'-(5-(2,3-ジクロロフェニル)-3-(ヒドロキシメチル)-6-メチルピラジン-2-イル)-1,3-ジヒドロスピロ[インデン-2,4'-ピペリジン]-6-カルボニトリル(化合物2)
LC-MS, (ES, m/z) : [M+H]+ = 426.
LC-MS, (ES, m/z) : [M+H]+ = 396.
LC-MS, (ES m/z): [M+H]+=380.
LC-MS, (ES, m/z): [M+H]+=327.
LC-MS, (ES, m/z): [M+H]+=430
LC-MS, (ES, m/z): [M+H]+=432.
LC-MS, (ES, m/z): [M+H]+=332.
LC-MS, (ES, m/z): [M+H]+=640.
LC-MS, (ES, m/z):[M+H]+=536.
LC-MS, (ES, m/z): [M+H]+=494.
1H NMR (400 MHz, D6-DMSO) δ = 8.02(s,1H) 7.78 -7.70 (m, 2H), 7.53 - 7.41(m, 3H), 5.31 (br 1H), 4.53 (s, 2H), 3.84 - 3.68 (m, 3H), 3.23-2.91 (m, 3H), 2.20 (s, 3H), 2.10 - 1.98 (m, 1H), 1.50- 1.45 (m, 4H).
(S)-N-(1-アミノ-1'-(5-(2,3-ジクロロフェニル)-3-(ヒドロキシメチル)-6-メチルピラジン-2-イル)-1,3-ジヒドロスピロ[インデン-2,4'-ピペリジン]-6-イル)メタンスルホンアミド(化合物3)
LC-MS, (ES m/z): [M+H]+=395.
LC-MS, (ES m/z): [M+H]+=498.
LC-MS, (ES m/z): [M+H]+=500.
LC-MS, (ES m/z): [M+H]+=400.
LC-MS, (ES m/z): [M+H]+=708.
LC-MS, (ES m/z): [M+H]+=605.
LC-MS, (ES m/z): [M+H]+=562.
1H NMR (400 MHz, D6-DMSO) δ = 9.59(br,1H) 7.74 (dd, J=7.9Hz, 1.7Hz, 1H), 7.60(t, J=3.5Hz, 1H),7.49(t, J=7.8Hz, 1H), 7.43(m, 1.7, 1H),7.19(d, J=8.1Hz, 1H), 7.08(m, 2.0 1H), 5.28(br, 1H) ,4.53 (s, 2H), 3.75 - 3.65 (m, 3H), 3.14-3.01 (m, 3H), 2.98 (s, 3H), 2.78 (d, J=15.7Hz, 1H), 2.20(s,3H), 2.09-1.89(m, 2H), 1.57- 1.29 (m, 2H).
(S)-1-(1-アミノ-1'-(5-(2,3-ジクロロフェニル)-3-(ヒドロキシメチル)-6-メチルピラジン-2-イル)-1,3-ジヒドロスピロ[インデン-2,4'-ピペリジン]-6-イル)プロパン-2-オール(化合物4)
LC-MS, (ES m/z): [M+H]+=449.
LC-MS, (ES m/z): [M+H]+=365.
LC-MS, (ES m/z): [M+H]+=673.
LC-MS, (ES m/z): [M+H]+=569.
LC-MS, (ES, m/z): [M+H]+=527.
1H NMR (400 MHz, D6-DMSO) δ = 7.81(s,1H) ,7.75(dd, J=8.0Hz, 2.0Hz, 1H), 7.51 -7.36 (m, 3H), 7.14(d, J=7.9Hz, 1H), 5.28(br 1H),4.93(br,1H), 4.53 (s, 2H), 3.74 - 3.65 (m, 3H), 3.10-3.04 (m, 3H), 2.78 (d, J=16Hz,1H)(s, 3H), 2.20(s, 3H), 2.11 - 1.93 (m, 1H), 1.57-1.44(m,3H), 1.43 (d, J=7.5Hz, 6H).
(S)-1-アミノ-1'-(5-(2,3-ジクロロフェニル)-3-(ヒドロキシメチル)-6-メチルピラジン-2-イル)-1,3-ジヒドロスピロ[インデン-2,4'-ピペリジン]-6-カルボキサミド(化合物5)
LC-MS, (ES, m/z): [M+H]+=450.
LC-MS, (ES, m/z): [M+H]+=350.
LC-MS, (ES, m/z) : [M+H]+ = 658.
LC-MS, (ES,m/z):[M+H]+= 554.
LC-MS, (ES, m/z):[M+H]+= 512.
1H NMR (400 MHz, D6-DMSO) δ = 8.37(S,1H), 8.20(s,1H), 7.87(d, J=10.4Hz, 1H),7.76 (dd, J = 7.8 Hz, 1.6Hz, 1H), 7.75(S,1H) ,7.51 - 7.47 (m, 1H), 7.46(dd, J=15.2Hz, 4.8Hz, 1H), 7.29(d, J=7.9Hz, 1H), 5.59 -5.31 (m, 3H),4.54 (s, 2H), 3.78 - 3.65 (m, 3H), 3.18 - 3.04 (m, 3H), 2.85 (d, J = 16.1 Hz, 1H), 2.20 (s, 3H), 2.12 - 1.88 (m, 1H), 1.61-1.41 (m, 3H).
LC-MS, (ES, m/z):[M+H]+= 315.
LC-MS,(ES, m/z): [M+H]+=586
LC-MS, (ES,m/z):[M+H]+= 482.
1H NMR (400 MHz, D6-DMSO) δ= 8.39(S,2H), 7.84(S,1H),7.73 (dd, J = 6.8 Hz, 2.7Hz, 1H), 7.49 -7.45 (m, 2H), 7.34 -7.32 (m, 1H), 7.21 - 7.16 (m, 2H), 4.00 -3.89 (m, 1H), 3.43-3.06 (m, 5H), 2.66 (d, J = 15.8 Hz, 1H), 2.20 (s, 3H), 1.90 - 1.67 (m, 2H), 1.52-1.15 (m, 2H).
LC-MS, (ES,m/z):[M+H]+= 297.
LC-MS, (ES,m/z):[M+H]+=568.
LC-MS, (ES,m/z):[M+H]+=463
1H NMR (400 MHz, D6-DMSO) δ=7.81-7.72(m,3H), 7.64(d, J=7.7Hz, 1H), 7.56 -7.44 (m, 3H), 4.67 -4.62 (m, 2H), 4.13 - 4.10 (m, 1H), 3.29- 3.17 (m, 3H), 2.69-2.67(m, 1H), 2.28 (s, 3H), 2.19- 2.12(m, 2H), 1.77-1.47 (m, 2H).
(S)-1-アミノ-1'-(5-(2,3-ジクロロフェニル)-3-(ヒドロキシメチル)-6-メチルピラジン-2-イル)-1,3-ジヒドロスピロ[インデン-2,4'-ピペリジン]-7-カルボニトリル(化合物8)
LC-MS, (ES, m/z) : [M+H]+ = 426.
LC-MS, (ES, m/z) : [M+H]+ = 396.
LC-MS, (ES, m/z) : [M+H]+ = 380.
LC-MS, (ES, m/z) : [M+H]+ = 327.
LC-MS, (ES, m/z) : [M+H]+ = 430.
LC-MS, (ES, m/z):[M+H]+=432.
LC-MS, (ES, m/z) : [M+H]+ = 332.
LC-MS, (ES, m/z) : [M+H]+ =640.
LC-MS, (ES, m/z): [M+H]+=536.
LC-MS, (ES, m/z) : [M+H]+ = 494.
1H NMR (400 MHz, D6-DMSO) δ = 7.74 (dd, J = 7.9 Hz, 1.7 Hz, 1H), 7.64 - 7.54 (m, 2H), 7.51 - 7.36 (m, 3H), 5.34 - 5.28 (m, 1H), 4.54 - 4.50 (m, 2H), 4.1 - 3.53 (m, 2H), 3.27 - 2.78 (m, 4H), 2.20 (s, 3H), 2.03 - 1.92 (m, 2H), 1.74 - 1.30 (m, 2H).
(S)-N-(1-アミノ-1'-(5-(2,3-ジクロロフェニル)-3-(ヒドロキシメチル)-6-メチルピラジン-2-イル)-1,3-ジヒドロスピロ[インデン-2,4'-ピペリジン]-5-イル)メタンスルホンアミド(化合物9)
LC-MS, (ES, m/z): [M+H]+=380.
LC-MS, (ES, m/z):[M+H]+=395.
LC-MS, (ES,m/z): [M+H]+=498.
LC-MS, (ES, m/z): [M+H]+=500.
LC-MS, (ES, m/z): [M+H]+=400.
LC-MS, (ES, m/z): [M+H]+=708.
LC-MS, (ES, m/z): [M+H]+=603.
LC-MS, (ES, m/z) : [M+H]+ = 562.
1H NMR (400 MHz, D6-DMSO) δ = 9.62 (s, 1H), 7.74 (dd, J = 7.8 Hz, 1.7 Hz, 1H), 7.51 - 7.42 (m, 2H), 7.27 (d, J = 7.8 Hz, 1H), 7.06 - 7.04 (m, 2H), 4.64 - 4.51 (m, 3H), 3.69 - 3.65 (m, 2H), 3.36 - 3.12 (m, 3H), 3.02 - 2.63 (m, 5H), 2.20 (s, 3H), 1.98 - 1.75 (m, 2H), 1.58 - 1.33 (m, 2H).
(S)-(3-(1-アミノ-1,3-ジヒドロスピロ[インデン-2,4'-ピペリジン]-1'-イル)-6-(2-アミノ-3-クロロピリジン-4-イル)-5-メチルピラジン-2-イル)メタノール(化合物10)
LC-MS, (ES, m/z): [M+H]+=455.
LC-MS, (ES,m/z): [M+H]+=372.
LC-MS, (ES,m/z): [M+H]+=527.
LC-MS, (ES,m/z): [M+H]+=797.
LC-MS, (ES, m/z): [M+H]+=493
LC-MS, (ES, m/z): [M+H]+=451.
LC-MS, (ES, m/z): [M+H]+=303.
LC-MS, (ES, m/z): [M+H]+=339.
LC-MS,(ES, m/z): [M+H]+=587.
LC-MS, (ES, m/z):[M+H]+=483.
LC-MS, (ES, m/z) : [M+H]+ = 455.
1H NMR (400 MHz, CDCl3) δ = 8.49 (s, 1H), 7.57 - 7.49 (m, 2H), 7.40 - 7.32 (m, 3H), 7.28 - 7.23 (m, 2H), 4.79 (d, J = 5.7 Hz, 2H), 4.06 (s, 1H), 3.66 - 3.56 (m, 3H), 3.26 - 3.11 (m, 3H), 2.77 (d, J = 15.8 Hz, 1H), 2.05 - 1.88 (m, 1H), 1.70 - 1.45 (m, 2H).
(S)-(3-(1-アミノ-1,3-ジヒドロスピロ[インデン-2,4'-ピペリジン]-1'-イル)-5-メチル-6-(2-(トリフルオロメチル)ピリジン-3-イル)ピラジン-2-イル)メタノール(化合物12)
LC-MS, (ES, m/z) : [M+H]+ = 274.
LC-MS, (ES,m/z): [M+H]+= 346.
LC-MS, (ES,m/z): [M+H]+=616.
LC-MS, (ES, m/z):[M+H]+=512.
LC-MS, (ES, m/z) : [M+H]+ = 470.
1H NMR (400 MHz, D6-DMSO) δ = 8.86 - 8.83 (m, 1H), 8.06 - 8.04 (m, 1H), 7.86 - 7.83 (m, 1H), 7.71 - 7.68 (m, 1H), 7.25 - 7.17 (m, 3H), 5.60 - 5.45 (m, 2H), 5.24 (t, J = 5.8 Hz, 1H), 4.51 (d, J = 5.7 Hz, 2H), 3.77 - 3.70 (m, 3H), 3.15 - 3.04 (m, 3H), 2.79 (d, J = 15.8 Hz, 1H), 2.17 (s, 3H), 2.05 - 1.96 (m, 2H), 1.57 - 1.28 (m, 2H).
(S)-(3-(5-アミノ-5,7-ジヒドロスピロ[シクロペンタ[b]ピリジン-6,4'-ピペリジン]-1'-イル)-6-(2,3-ジクロロフェニル)-5-メチルピラジン-2-イル)メタノール(化合物13)
LC-MS, (ES, m/z):[M+H]+=341.
LC-MS, (ES, m/z):[M+H]+=338.
LC-MS,(ES, m/z):[M+H]+=303.
LC-MS, (ES,m/z):[M+H]+=512.
1H NMR (400 MHz, D6-DMSO) δ 8.40 (d, J = 5.4 Hz, 1H), 7.87 - 7.68 (m, 2H), 7.49 (t, J = 7.8 Hz, 1H), 7.44 (dd, J = 7.6, 1.7 Hz, 1H), 7.24 (dd, J = 7.5, 5.0 Hz, 1H), 5.32 (t, J = 4.7 Hz, 1H), 4.54 (d, J = 4.5 Hz, 2H), 4.15 (s, 1H), 3.87 - 3.68 (m, 2H), 3.14 (dd, J = 14.3, 8.4 Hz, 3H), 2.87 (d, J = 16.4 Hz, 1H), 2.21 (s, 3H), 1.91 (dd, J = 20.9, 11.4 Hz, 2H), 1.59 (d, J = 13.8 Hz, 1H), 1.36 (d, J = 12.4 Hz, 1H).
LC-MS,(ES,m/z):[M+H]+=229.7
LC-MS, (ES,m/z):[M+H]+=264.1.
LC-MS, (ES,m/z): [M+H]+=462.7.
LC-MS, (ES,m/z): [M+H]+=712.7.
生物活性実験
SHP2タンパク質活性のスクリーニング方法は、蛍光検出により確立されている。基本原理は、SHP2がホスファターゼとして、DiFMUPの脱燐を触媒してDiFMUおよび遊離リン酸基を形成することができることにある。生成物であるDiFMUは340nmの励起(excitation)下で蛍光を発し、450nmの発光を収集した。低分子化合物とSHP2の結合によりSHP2酵素の活性を阻害できれば、検出される450nmの発光が弱くなり、最終的には蛍光値の強度によりSHP2酵素の活性が反映されることになる。
細胞増殖阻害スクリーニング方法は、Promega社のCellTier-Glu(登録商標)試験試薬により確立されている。
パッチクランプ増幅器システム(Multiclamp 700B Amplifier)(AXON)、オリンパス顕微鏡(Olympus IX51/71/73)およびMP285マイクロマニピュレーターを使用した。
R1およびR2はそれぞれ、-H、-CH3、-NH2、-C(O)O(CH2)nCH3、-CN、-OH、-CH2OH、-C(O)NH2または-CH(OH)CH3から独立して選択され;
R3は、H、C1-6アルキル、-CF3、ハロゲン、-SO2CH3、-OCH3、-CN、-C(O)NH2、-NHSO 2 CH 3、 -NSO(CH 3 ) 2 、-CHn(CH3)2-nOH、-C(O)CH3または-OCF3から選択され;
R4、R5、R6、R7およびR8はそれぞれ、-H、-Cl、-CH3、-Br、-CF3、CH3O-、CH3SO2-、=O、CH3NH-および-NH2から独立して選択され;
Y1、Y2、Y3およびY4はそれぞれ、CまたはNから独立して選択され;そして
n=0または1である]
の構造を有する。
(S)-2-(1-アミノ-1'-(5-(2,3-ジクロロフェニル)-3-(ヒドロキシメチル)-6-メチルピラジン-2-イル)-1,3-ジヒドロスピロ[インデン-2,4'-ピペリジン]-6-イル)プロパン-2-オール(化合物4)
(R)-N-((S)-4-シアノ-1'-tert-ブトキシカルボニル-1,3-ジヒドロスピロ[インデン-2,4’-ピペリジン]-3-イル)-2-メチルプロパン-2-スルフィンアミド(140mg)から粗生成物(107mg)を得た。
LC-MS, (ES, m/z) : [M+H]+ = 332.
LC-MS, (ES, m/z):[M+H]+=395.
LC-MS, (ES,m/z): [M+H]+=372.
Claims (9)
- 式(I):
R1およびR2はそれぞれ、-CH3、-NH2、-CH2OH、-C(O)O(CH2)nCH3、-CN、-H、-OH、-C(O)NH2または-CH(OH)CH3から独立して選択され;
R3は、H、C1-6アルキル、-CF3、ハロゲン、-SO2CH3、-OCH3、-CN、-C(O)NH2、-NHnSO3-m(CH3)m、-CHn(CH3)mOH、-OCF3または-C(O)CH3から選択され;
Y1、Y2、Y3およびY4はそれぞれ、-C-または-N-から独立して選択され;
n=0または1であり;そして
m=1または2である]
で示される、SHP2ホスファターゼアロステリック阻害物質の光学異性体化合物またはその薬学的に許容できる塩。 - 阻害物質が、式(II):
R1およびR2はそれぞれ、-H、-CH3、-NH2、-C(O)O(CH2)nCH3、-CN、-OH、-CH2OH、-C(O)NH2または-CH(OH)CH3から独立して選択され;
R3は、H、C1-6アルキル、-CF3、ハロゲン、-SO2CH3、-OCH3、-CN、-C(O)NH2、-NHSO2CH3、-NSO(CH3)2、-CHn(CH3)2-nOH、-C(O)CH3または-OCF3から選択され;
R4、R5、R6、R7およびR8はそれぞれ、-H、-Cl、-CH3、-Br、-CF3、CH3O-、CH3SO2-、=O、CH3NH-および-NH2から独立して選択され;
Y1、Y2、Y3およびY4はそれぞれ、CまたはNから独立して選択され;そして
n=0または1である]
の構造を有する、請求項1に記載の化合物またはその薬学的に許容できる塩。 - R1が、-CH3または-NH2から選択され;
R2が、-CH2OH、-C(OH)CH3、-C(O)O(CH2)nCH3、-CN、-Hまたは-C(O)NH2から選択される、請求項2に記載の化合物またはその薬学的に許容できる塩。 - 腫瘍疾患を処置するための医薬の調製における、請求項1~8のいずれか一項に記載のSHP2ホスファターゼアロステリック阻害物質の光学異性体化合物またはその薬学的に許容できる塩の使用。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910515196.0 | 2019-06-14 | ||
CN201910515196 | 2019-06-14 | ||
CN201911068821.8 | 2019-11-04 | ||
CN201911068821 | 2019-11-04 | ||
CN202010056703 | 2020-01-17 | ||
CN202010056703.1 | 2020-01-17 | ||
CN202010517372 | 2020-06-09 | ||
CN202010517372.7 | 2020-06-09 | ||
PCT/CN2020/095795 WO2020249079A1 (zh) | 2019-06-14 | 2020-06-12 | 一种shp2磷酸酶变构抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022535998A true JP2022535998A (ja) | 2022-08-10 |
JP7335003B2 JP7335003B2 (ja) | 2023-08-29 |
Family
ID=73780909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021574766A Active JP7335003B2 (ja) | 2019-06-14 | 2020-06-12 | Shp2ホスファターゼアロステリック阻害物質 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220388977A1 (ja) |
EP (1) | EP3984999A4 (ja) |
JP (1) | JP7335003B2 (ja) |
KR (1) | KR20220061087A (ja) |
CN (4) | CN117209470A (ja) |
TW (1) | TW202112761A (ja) |
WO (1) | WO2020249079A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
WO2022242767A1 (zh) * | 2021-05-21 | 2022-11-24 | 石药集团中奇制药技术(石家庄)有限公司 | 螺环类化合物及其用途 |
WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018172984A1 (en) * | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2019051084A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER |
WO2019183367A1 (en) * | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
WO2020073949A1 (zh) * | 2018-10-10 | 2020-04-16 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8575167B2 (en) * | 2007-02-06 | 2013-11-05 | Takeda Pharmaceutical Company Limited | Spiro compounds having stearoyl-CoA desaturase action |
WO2018041248A1 (zh) * | 2016-09-01 | 2018-03-08 | 北京赛林泰医药技术有限公司 | Bcl-2选择性抑制剂及其制备和用途 |
WO2020063760A1 (en) * | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
-
2020
- 2020-06-12 CN CN202310905773.3A patent/CN117209470A/zh active Pending
- 2020-06-12 KR KR1020227001357A patent/KR20220061087A/ko not_active Application Discontinuation
- 2020-06-12 TW TW109119941A patent/TW202112761A/zh unknown
- 2020-06-12 CN CN202080043751.5A patent/CN114008035A/zh active Pending
- 2020-06-12 EP EP20822079.8A patent/EP3984999A4/en active Pending
- 2020-06-12 US US17/618,835 patent/US20220388977A1/en active Pending
- 2020-06-12 WO PCT/CN2020/095795 patent/WO2020249079A1/zh unknown
- 2020-06-12 CN CN202310907352.4A patent/CN117209471A/zh active Pending
- 2020-06-12 CN CN202310903760.2A patent/CN117209475A/zh active Pending
- 2020-06-12 JP JP2021574766A patent/JP7335003B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018172984A1 (en) * | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
WO2019051084A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER |
WO2019183367A1 (en) * | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
WO2020073949A1 (zh) * | 2018-10-10 | 2020-04-16 | 江苏豪森药业集团有限公司 | 含氮杂芳类衍生物调节剂、其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN114008035A (zh) | 2022-02-01 |
CN117209475A (zh) | 2023-12-12 |
EP3984999A4 (en) | 2023-11-22 |
KR20220061087A (ko) | 2022-05-12 |
CN117209470A (zh) | 2023-12-12 |
US20220388977A1 (en) | 2022-12-08 |
TW202112761A (zh) | 2021-04-01 |
WO2020249079A1 (zh) | 2020-12-17 |
EP3984999A1 (en) | 2022-04-20 |
CN117209471A (zh) | 2023-12-12 |
JP7335003B2 (ja) | 2023-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7335003B2 (ja) | Shp2ホスファターゼアロステリック阻害物質 | |
US9918985B2 (en) | Compounds and their use as BACE inhibitors | |
JP6506845B2 (ja) | B型肝炎ウイルス感染症の治療及び予防のための新規テトラヒドロピリドピリミジン類及びテトラヒドロピリドピリジン類 | |
CN107011348B (zh) | 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物 | |
JP5406039B2 (ja) | タンパク質キナーゼ阻害剤として有用な5−シアノ−4−(ピロロ[2,3b]ピリジン−3−イル)−ピリミジン誘導体 | |
CA3075727A1 (en) | Pyridazinones and methods of use thereof | |
AU2018344926A1 (en) | Chemical compounds | |
RU2742485C2 (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
TW202216686A (zh) | 藉由使egfr抑制劑與e3連接酶配位體結合來降解(egfr)以及使用方法 | |
JP2021514346A (ja) | 肝再生促進又は肝細胞死の抑制もしくは防止のためのプロテインキナーゼmkk4阻害剤 | |
KR102454129B1 (ko) | 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도 | |
KR20200083529A (ko) | 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물 | |
EP3694330A1 (en) | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
JP2024508235A (ja) | 三環-アミド-二環prmt5阻害剤 | |
JP6425717B2 (ja) | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン | |
TW202140478A (zh) | 藉由軛合btk抑制劑與e3連接酶配位基降解布魯頓氏酪胺酸激酶(btk)及其使用方法 | |
CN109651358B (zh) | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 | |
CA3213088A1 (en) | Substituted 1-aryl-1'-heteroaryl compounds, substituted 1,1'-biheteroaryl compounds, and methods using same | |
JP7406008B2 (ja) | Cdk9阻害剤としての多環式アミド系誘導体、その調製方法及び用途 | |
CN116322700A (zh) | 新型plk1降解诱导化合物 | |
WO2018234953A1 (en) | DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | |
CN114621186A (zh) | 作为ras信号通路调控剂的杂环化合物 | |
TW202214634A (zh) | 雜環化合物及其衍生物 | |
RU2800292C2 (ru) | Химические соединения | |
US20240124448A1 (en) | Tyk2 inhibitors and compositions and methods thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220210 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220210 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230207 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230508 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230711 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230809 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7335003 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |